WntResearch: Possible paradigm shift in pre-surgical treatment
Initiating Coverage
2024-06-13
07:00
Redeye initiates coverage of WntResearch, a Swedish biotechnology company specialised in oncology. Its phase II drug candidate, Foxy-5, focuses on colon cancer and intends to decrease tumors and reduce cancer spread. Our fair value range suggests a significant upside potential in the share, and we argue that upcoming interim data and a potential licensing deal are two major catalysts in the short term.
GM
RR
Gustaf Meyer
Richard Ramanius
Disclosures and disclaimers